| | 
Part, Chapter, Paragraph
1 I, 2. 5. 0(3) | CAT_PREREL_YEAR_2008_MONTH_12/2-16122008-EN-AP.PDF~
2 I, 2. 10. 4 | transcription account for 11% and 12%. While about half of the
3 I, 2. 11 | Perspectives, 115(1), 5-12~Suhrcke M, McKee M, Sauto
4 I, 3. 1 | the United Kingdom, and 12-13% in Italy and the Netherlands;
5 I, 3. 2 | high natural increase. The 12 new Member States have a
6 I, 3. 3 | show that the trends in the 12 new Member States are fluctuating
7 II, 4. 1 | duration is much larger in the 12 new Member States (8 years)
8 II, 4. 2 | causes (causes 10, 11 and 12 in table 3) has decreased
9 II, 4. 2 | countries and for women in 12 countries, even though for
10 II, 4. 2 | impact on life expectancy in 12 of the 13 countries. In
11 II, 5. 2. 5 | was officially launched on 12 June 2007 before the European
12 II, 5. 2. 7 | 2006 [htt ] (accessed on 12.07.07).~EUROCISS Working
13 II, 5. 2. 7 | EUROSTAT [htt ] (accessed on 12.07.07).~Evans A, Tolonen
14 II, 5. 2. 7 | women and men: findings on 12 Italian population samples.
15 II, 5. 2. 7 | HFA-DB [htt ] (accessed on 12.07.07).~WHO MONICA Project [
16 II, 5. 2. 7 | fi/monica/] (accessed on 12.07.07).~WHO Regional Office
17 II, 5. 3. 5 | and in Estonia for women (12 deaths per 100,000). Incidence
18 II, 5. 3. 6 | lung (European mean: 12%), breast (European mean:
19 II, 5. 3. 9 | Health Strategies in Europe, 12 – 13 July 2007, Strategies
20 II, 5. 3. 9 | Health Strategies in Europe, 12 – 13 July 2007, Strategies
21 II, 5. 4. 2 | 000 population 0–14 years~12~HES/HIS Registry~Prevalence
22 II, 5. 4. 2 | 100,000 general population~12~National Registry~Annual
23 II, 5. 4. 2 | European Standard Population~12~National Registry~Acronyms:~
24 II, 5. 4. 2 | and a HbA1c tested in last 12 months~16~Percent of diabetic
25 II, 5. 4. 2 | lipid profile in the last 12 months~14~Percent of diabetic
26 II, 5. 4. 2 | subjects tested in the last 12 months with total cholesterol>
27 II, 5. 4. 2 | subjects tested in the last 12 months with LDL>2.6 mmol/
28 II, 5. 4. 2 | subjects tested in the last 12 months with HDL<1.15 mmol/
29 II, 5. 4. 2 | subjects tested in the last 12 months with triglycerides >
30 II, 5. 4. 2 | 2.3 mmol/l (>2.0 mmol/l)~12~Percent of diabetic subjects
31 II, 5. 4. 2 | microalbuminuria in the last 12 months~12~Percent of diabetic
32 II, 5. 4. 2 | microalbuminuria in the last 12 months~12~Percent of diabetic subjects
33 II, 5. 4. 2 | microalbuminuria in the last 12 months, with an abnormal
34 II, 5. 4. 2 | pressure measurement in last 12 months~14~Percent of of
35 II, 5. 4. 2 | blood pressure in the last 12 months showing a value >
36 II, 5. 4. 2 | fundus inspection in the last 12 months~11~Percent of diabetic
37 II, 5. 4. 2 | subjects tested in the last 12 months, with proliferative
38 II, 5. 4. 2 | proliferative retinopathy in last 12 months~6~Percent of diabetic
39 II, 5. 4. 2 | serum creatinine in last 12 months~13~Percent of diabetic
40 II, 5. 4. 2 | haemoglobin (HbA1c) in the last 12 months is measured as the
41 II, 5. 4. 2 | HbA1c measured in the last 12 months. EUCID results were
42 II, 5. 4. 2 | cholesterol in the last 12 months is an important parameter
43 II, 5. 4. 2 | cholesterol tested in the last 12 months.~Total cholesterol
44 II, 5. 4. 2 | cholesterol tested in last 12 months showing a total cholesterol
45 II, 5. 4. 2 | cholesterol in the last 12 months is another important
46 II, 5. 4. 2 | LDL-cholesterol tested in the last 12 months.~LDL cholesterol
47 II, 5. 4. 2 | LDL-cholesterol tested in the last 12 months and presenting a
48 II, 5. 4. 2 | cholesterol in the last 12 months is also taken as
49 II, 5. 4. 2 | LDL-cholesterol tested in the last 12 months.~HDL cholesterol
50 II, 5. 4. 2 | HDL-cholesterol tested in the last 12 months and HDL cholesterol
51 II, 5. 4. 2 | triglycerides in the last 12 months is the last important
52 II, 5. 4. 2 | triglycerides tested in the last 12 months.~Triglycerides level >
53 II, 5. 4. 2 | cholesterol tested in last 12 months showing a total cholesterol
54 II, 5. 4. 2 | proteinuria exists) in the last 12 months.~An abnormal level
55 II, 5. 4. 2 | proteinuria tested in last 12 months with a microalbuminuria
56 II, 5. 4. 2 | pressure measured in the last 12 months. The median is 95%
57 II, 5. 4. 2 | pressure measured in the last 12 months and reported a diastolic
58 II, 5. 4. 2 | fundus inspected in last 12 months. This indicator is
59 II, 5. 4. 2 | fundus inspected in the last 12 months and were diagnosed
60 II, 5. 4. 2 | fundus inspected in the last 12 months and were diagnosed
61 II, 5. 4. 2 | creatinine tested during the last 12 months.~Renal failure is
62 II, 5. 4. 2 | creatinine tested in the last 12 months and End Stage Renal
63 II, 5. 4. 3 | Poland (15%) and Denmark (12%) showing the highest values.
64 II, 5. 4. 3 | haemoglobin (HbA1c) in the last 12 months. OECD data (Armesto
65 II, 5. 4. 3 | cholesterol in the last 12 months. EUCID crude data
66 II, 5. 4. 3 | months. EUCID crude data from 12 countries are consistent
67 II, 5. 4. 3 | cholesterol in the last 12 months. The EUCID indicator
68 II, 5. 4. 3 | cholesterol in the last 12 months. The EUCID indicator
69 II, 5. 4. 3 | triglycerides in the last 12 months. EUCID crude data
70 II, 5. 4. 3 | and 46% (Sweden) across 12 countries, with a median
71 II, 5. 4. 3 | among diabetics. In EUCID 12 countries provided data;
72 II, 5. 4. 3 | showing a variation between 12% (Ireland) and 84% (Netherlands).
73 II, 5. 4. 3 | fundus inspected in the last 12 months and were diagnosed
74 II, 5. 4. 4 | in Europe ranges between 12% (Netherlands) and 25% (
75 II, 5. 4. 8 | mellitus, Diabet Med. 1995 Mar;12(3):271-6~Beck, P, Battlogg,
76 II, 5. 5.Int(21)| and of the Council of 22.12.1998, Official Journal L26/
77 II, 5. 5. 1 | 1 presents lifetime and 12 month prevalence rates (%)
78 II, 5. 5. 1 | Table 5.5.1.1 Lifetime and 12 month prevalence of mood
79 II, 5. 5. 1 | no mental disorder during 12 months, ESEMeD Study.~ ~
80 II, 5. 5. 1 | variations over approximately 12 years is given in Table
81 II, 5. 5. 2 | International (ADI). For this study, 12 international experts conducted
82 II, 5. 5. 3 | increases with age: from 12% for 11-year-olds to 23%
83 II, 5. 5. 3 | dissatisfaction increases with age: 12% for 11-year-olds, 23% for
84 II, 5. 5. 3 | article online, accessed on 12 March 2007).~The Cleveland
85 II, 5. 5. 3 | article online, accessed on 12 March 2007).~World Health
86 II, 5. 5. 3 | data from Germany from the 12-months period between July
87 II, 5. 5. 3 | with the highest SMR of 12.86. The authors found that
88 II, 5. 5. 3 | seeking in these surveys was 12 months (Kohn et al, 2004).~
89 II, 5. 5. 3 | treatment discontinuation over 12 months in patients with
90 II, 5. 5. 3 | project. Qual Saf Health Care 12:18-23.~Andlin-Sobocki P,
91 II, 5. 5. 3 | in Europe. Eur J Neurol 12 Suppl 1:1-27.~Andlin-Sobocki
92 II, 5. 5. 3 | in Europe. Eur J Neurol 12 Suppl 1:74-77.~Andrews G,
93 II, 5. 5. 3 | 5-14 years - = 6-12 years MR = Medical record
94 II, 5. 5. 3 | policies~Prevalent cohorts~32~12.4~2.6~Preston and Clarke,
95 II, 5. 5. 3 | institution~Cross-sectional~105~12.0~8.7~Alstrom, 1942 (*)~ ~
96 II, 5. 5. 3 | 5-year remission rate at 12-30 years of age children
97 II, 5. 5. 3 | Exceptions (ban)~___ __~Belgium I 12 months First unprovoked
98 II, 5. 5. 3 | with driving~Denmark I 12 months Seizures during sleep (
99 II, 5. 5. 3 | II - Prohibited~Finland I 12 months First unprovoked
100 II, 5. 5. 3 | II - Prohibited~France I 12 months Seizures only on
101 II, 5. 5. 3 | previous 3 years~Germany I 12 months Single seizures or
102 II, 5. 5. 3 | idiopathic (24 months)~Ireland I 12 months Seizures during sleep
103 II, 5. 5. 3 | Prohibited~Netherlands I 12 months First unprovoked
104 II, 5. 5. 3 | activity)~ ~ ~Norway I 12 months Drugs stolen or last
105 II, 5. 5. 3 | months (taxi) -~Switzerland I 12 months -~United Kingdom
106 II, 5. 5. 3 | months -~United Kingdom I 12 months Seizures during sleep
107 II, 5. 5. 3 | systematic review. Eur J Neurol 12:245-253.~Fraser RT, Clemmons
108 II, 5. 5. 3 | Greece. Eur Neurol 49:8-12.~Poser CM, Paty DW, Scheinberg
109 II, 5. 5. 3 | After a mean duration of 12 years, patients require
110 II, 5. 5. 3 | Rosati et al, 1980) to 12,500/100,000 for institutionalised
111 II, 5. 5. 3 | variations in rates (65.6 to 12,500/100,000) may be the
112 II, 5. 5. 3 | the highest prevalence of 12,500/100,000 was obtained
113 II, 5. 5. 3 | productivity loss due to 12 major diseases in 6 countries
114 II, 5. 5. 3 | in Europe. Eur J Neurol 12 Suppl 1:1-27.~Baldereschi
115 II, 5. 5. 3 | Rotterdam Study. Neurology 45(12):2143-2146.~de Rijk MC,
116 II, 5. 5. 3 | in Europe. Eur J Neurol 12 Suppl 1:68-73.~Logroscino
117 II, 5. 5. 3 | atrophy. J Neural Transm 112(12):1605-1612.~von Campenhausen
118 II, 5. 6. 3 | 6 per 1000 for men and 3-12 per 1000 for women. In all
119 II, 5. 6. 4 | common reason (Table 5.6.12). (European Commission (
120 II, 5. 6. 4 | Conditions)~ ~Table 5.6.12. Distribution (in per cent)
121 II, 5. 6. 6 | and women. Osteoporos Int 12:555-558~Palmer KT, Walsh
122 II, 5. 7. 3 | ml/min per 1.74 m2 ) of 12.1 cases per million of the
123 II, 5. 7. 3 | adults are available for 12 countries. The data for
124 II, 5. 7. 3 | cohort 1990-1994) and 12% (cohort 1995-1999) lower
125 II, 5. 8. 3 | were assessed at 22% and 12% in never-smokers (Pelkonen
126 II, 5. 8. 3 | women respectively to: mild 12.3 and 7.3%, moderate 4.5
127 II, 5. 8. 3 | Disease (BOLD) studies (12 centres; 5 European centres)
128 II, 5. 8. 4 | smokers, and to 22% and 12% in never-smokers (Pelkonen
129 II, 5. 8. 5 | was 16.3%, whereas it was 12.0% in those with normal
130 II, 5. 8. 6 | showed that in the last 12 months of life, decedents
131 II, 5. 8. 6 | term care setting (41% vs. 12.5%, p<0.05) and to receive
132 II, 5. 8. 7 | lung cancer in the last 12 months of life. Respir Med
133 II, 5. 9. FB | meta-analysis including 12 studies examined the effect
134 II, 5. 9. 3 | 2.63 and 95% CI = 2.20-3.12 for 1974-1979 vs 1953-1958
135 II, 5. 9. 3 | Figure 5.9.1. Wheeze in last 12 months in ECHRS and ISAAC
136 II, 5. 9. 3 | data available indicate a 12.9% of prevalence in children,
137 II, 5. 9. 3 | in children, Czech Rep. 12.5%, Croatia 12.1%, Serbia
138 II, 5. 9. 3 | Czech Rep. 12.5%, Croatia 12.1%, Serbia 11.6%, Iceland
139 II, 5. 9. 4 | relative risk (RR) 1.32 (1.12, 1.56), even in those with
140 II, 5. 9. 4 | present, RR 1.01 (0.91, 1.12) for wheeze and 1.02 (0.
141 II, 5. 9. 4 | caused by grass pollen (12.7%), followed by house dust
142 II, 5. 9. 4 | s diagnosis of asthma - 12.4% of the males and 8.0%
143 II, 5. 9. 4 | et al, 2007) performed in 12 I Italian centres, showed
144 II, 5. 9. 7 | hay fever, and eczema in 12-14 year olds in the British
145 II, 5. 9. 7 | J Laryngol Otol. Dec;117(12):946-50.~ ~L I (2008): Tobacco smoke
146 II, 5. 10. 1 | particular food, and about 12% declare to experience such
147 II, 5. 10. 3 | conducted on young adults of 12 European countries plus
148 II, 5. 10. 3 | ECRHS project estimates in 12.2% the prevalence of self-reported
149 II, 5. 10. 3 | adults and children was about 12% (Rona et al, 2007).~ ~Figure
150 II, 5. 11. 3 | Danish school children (12-16 yrs)~Lifetime prevalence=
151 II, 5. 11. 3 | Danish school children (12-16 yrs)~Prevalence=15%~Mortz
152 II, 5. 11. 3 | Danish school children aged 12-16 yrs~Point prevalence=
153 II, 5. 11. 3 | from 24.8% to 9.2% over a 12-year period (CS Jensen et
154 II, 5. 11. 3 | and upper limbs for SCC (12% in men and 12.5% in women) (
155 II, 5. 11. 3 | for SCC (12% in men and 12.5% in women) (Plesko et
156 II, 5. 11. 3 | countries (28 500 cases and 12 000 deaths) (Ferlay et al,
157 II, 5. 12 | 5.12. Liver cirrhosis~ ~
158 II, 5. 12. 1 | 5.12.1. Introduction~ ~In the
159 II, 5. 12. 2 | 5.12.2. Data sources~ ~ ~Official
160 II, 5. 12. 3 | 5.12.3. Data description and
161 II, 5. 12. 3 | been reported in Figures 5.12.1 (A and B) and 5.12.2 (
162 II, 5. 12. 3 | Figures 5.12.1 (A and B) and 5.12.2 (A and B).~ ~ ~ ~Table
163 II, 5. 12. 3 | A and B).~ ~ ~ ~Table 5.12.1 gives the age-standardized
164 II, 5. 12. 3 | in percentage.~ ~Table 5.12.1. Age-adjusted (world population)
165 II, 5. 12. 3 | Spain had rates between 12 and 15/100,000, and Portugal
166 II, 5. 12. 3 | 8 to 20.3, Bulgaria from 12.5 to 19.4, Poland from 13.
167 II, 5. 12. 3 | from all countries (Table 5.12.2), but trends were similar
168 II, 5. 12. 3 | 24-30/100,000).~ ~Table 5.12.2. Age-adjusted (world population)
169 II, 5. 12. 3 | countries are given in Table 5.12.3 for men and in Table 5.
170 II, 5. 12. 3 | 3 for men and in Table 5.12.4 for women. Given the substantial
171 II, 5. 12. 3 | from Ireland.~ ~Table 5.12.3. Joinpoint regression
172 II, 5. 12. 3 | countries, 1970-2002~ ~Table 5.12.4. Joinpoint regression
173 II, 5. 12. 4 | 5.12.4. Risk factors~ ~The patterns
174 II, 5. 12. 5 | 5.12.5. Control tools and policies~ ~
175 II, 5. 12. 6 | 5.12.6. Future developments~ ~
176 II, 5. 12. 7 | 5.12.7. References~ ~Alter MJ,
177 II, 5. 12. 7 | prevention. Epidemiol Rev 12:221-227.~ ~Shepard CW, Finelli
178 II, 5. 14. 1 | out normally – age 10 to 12 – allows adequate dental
179 II, 5. 14. 2 | present per children at 6 and 12 years of age.~Numerator:
180 II, 5. 14. 2 | present per children at 6 and 12 years of age.~Denominator:
181 II, 5. 14. 2 | number of children at 6 and 12 years of age surveyed.~ ~
182 II, 5. 14. 2 | population in the age group 12, 15, 18 and 35-44 and 65-
183 II, 5. 14. 2 | individuals in the age group 12, 15, 18 and 35-74 years
184 II, 5. 14. 2 | individuals in the age group 12, 15, 18 and 35-74 years
185 II, 5. 14. 2 | status is recommended at age 12 and 15.~ ~d. Edentulous
186 II, 5. 14. 3 | serious decay threshold at age 12, varying around 1-1.5 score
187 II, 5. 14. 3 | programmes for children. For 12-year-olds the United Kingdom
188 II, 5. 14. 3 | 5.14.1. Dental Health in 12 year-old children in selected
189 II, 5. 14. 3 | management. In France, 40% of 12-year olds have no caries
190 II, 5. 14. 3 | within European countries (12.8% in Italy, 16.3% in France,
191 II, 5. 14. 3 | a random sample of 1379 12-year old children in Leicestershire
192 II, 5. 14. 3 | 6-year-olds and 55.6% of 12-year-olds; 17.8% of children
193 II, 5. 14. 3 | Figure 5.14.3. Children aged 12 with a dental contact within
194 II, 5. 15. 3 | the age of 1 and 5 and to 12.5% of deaths between 5 and
195 II, 5. 15. 6 | Available at: htt , (accessed 12.05.2007).~ ~European Commission (
196 II, 5. 15. 6 | Available At:~htt m (accessed 12.05.2007)~Eurordis (2005):
197 II, 5. 15. 6 | Available at:~htt 8 (accessed 12.05.2007)~Haffner ME (2006):
198 II, 6. 3. 3 | decreasing trend. In 2005, 12 945 syphilis cases were
199 II, 6. 3. 5 | the EU in early 2001, and 12 European countries have
200 II, 6. 3. 6 | 000) followed by Finland (12.2 per 100 000) reporting
201 II, 6. 3. 6 | 25 countries. Latvia (2.12 per 100 000), followed by
202 II, 7. 1 | corresponding to about 12% of the entire European
203 II, 7. 3. 1 | Roughly 60 million – or 12% - out of 500 million EU
204 II, 7. 3. 4 | in Chapter 6.2. Figure 7.12. Non-fatal work place accidents
205 II, 7. 3. 4 | working days.~ ~Figure 7.12. Non-fatal work place accidents
206 II, 7. 4. 3 | were bicyclists. Only about 12% of cyclist injuries have
207 II, 8. 1. 3 | considerably restricted were about 12%) in the age group 55-64.
208 II, 8. 1. 3 | support and understanding (12%) and assistance with mobility (
209 II, 8. 1. 3 | with strong limitations are 12% lower, while those of women
210 II, 8. 2. 2 | Ophtalmic Epidemiology 12:243-250.~European Union
211 II, 9 | having got drunk in the last 12 months peaks in Denmark (
212 II, 9 | used it in the previous 12 months. Regular use of cannabis (
213 II, 9 | 39 times in the previous 12 months) is highest (15%
214 II, 9. 1. 1 | Gynecol Scand 2000;79(2):107-12.~ ~Huang DY, Usher RH, Kramer
215 II, 9. 1. 1 | Med Child Neurol 2000;42(12):816-24.~ ~Stephenson PA,
216 II, 9. 1. 1 | obstetrical interventions in 12 countries. Paediatr Perinat
217 II, 9. 1. 2 | Diagnosis, Vol 24, pp 908-12.~Garne E et al (1999): "
218 II, 9. 2. 3 | or more in the previous 12 months (HBSC, 2004). Unintentional
219 II, 9. 2. 3(2) | wheezing in the previous 12-month period in 13- to 14-
220 II, 9. 2. 4 | having got drunk in the last 12 months peaks in Denmark (
221 II, 9. 2. 4 | used it in the previous 12 months. Regular use of cannabis (
222 II, 9. 2. 4 | 39 times in the previous 12 months) is highest (15%
223 II, 9. 2. 7 | Birthweight. NeoReviews Vol.5 No.12 2004 e522. American Academy
224 II, 9. 2. 7 | 20drinking%22 ] (accessed 12.01.07)~ ~Ståhl T, Wismar
225 II, 9. 2. 7 | Copenhagen, Bucharest, 12 September 2005~ ~WHO (2006)
226 II, 9. 3. 1 | recognized to have occurred after 12 consecutive months of amenorrhea
227 II, 9. 3. 1 | populations have close to 12% disability. There is a
228 II, 9. 3. 1 | serum level is > 346 ng/dL (12 nmol/L) ART is not necessary,
229 II, 9. 3. 1 | Journal of Impotence Research. 12(6): p. 305-311.~ ~British
230 II, 9. 3. 1 | Eurosurveillance weekly 12, on-line article available
231 II, 9. 3. 1 | Journal of Neurology, Volume 12, Number 4, April 2005 ,
232 II, 9. 3. 1 | Article online,accessed 12.06)~ ~International Obesity
233 II, 9. 3. 2 | Gynecol Scand 2000;79(2):107-12.~ ~Huang DY, Usher RH, Kramer
234 II, 9. 3. 2 | obstetrical interventions in 12 countries. Paediatr Perinat
235 II, 9. 3. 2 | Med Child Neurol 2000;42(12):816-24.~ ~Temmerman M,
236 II, 9. 3. 3 | coital act during the last 12 months;~· percentage of
237 II, 9. 3. 3 | Official Journal C 271 E , 12/11/2003 P. 0369 - 0374~Facultes
238 II, 9. 4. 2 | project, carried out in 12 European countries, was
239 II, 9. 4. 7 | Gerontol A Biol Sci Med Sci, (12), p.1277-84.~DECODE study
240 II, 9. 5. 3 | there were an estimated 12.9 million incidents of domestic
241 II, 9. 5. 5 | Council Conclusions of 16.12.2005 on the implementation
242 II, 9. 5. 6 | Available at:~htt p~(Accessed 12.07.07)~ ~Age Concern (2007b):
243 II, 9. 5. 6 | Available at:~htt 4 (accessed 12.07.07)~ ~Cutler D, Deaton
244 II, 9. 5. 6 | of health. Soc Sci Med 58(12):2585-2600~ ~De Smedt M, (
245 II, 9. 5. 6 | Available at: (accessed 12.07.07)~ ~Iredale R, Reid
246 II, 9. 5. 6 | of Women’s Studies, Vol 12(3): 377-395; SAGE Publications~ ~
247 II, 9. 5. 6 | Biomarkers Prev. 2006 Dec;15(12):2494-501~ ~Middle C, Johnson
248 II, 9. 5. 6 | Available at: (accessed 12.07.07)~ ~New South Wales
249 II, 9. 5. 6 | Copenhagen, Bucharest, 12 September 2005. Available
250 II, 9. 5. 6 | Available at:~htt f (accessed 12.07.07)~ ~WHO: Intimate partner
251 II, 9. 5. 6 | Available at:~htt f (accessed 12.07.07)~ ~WHO (2000): Women’
252 II, 9. 5. 6 | Available at: (accessed 12.07.07)~ ~Women’s Health
253 II, 9. 5. 6 | Available at: (accessed 12.07.07)~ ~
254 III, 10. 1. 3 | interaction. Arch Dermatol 136(12):1544-6.~Szklo M, Nieto
255 III, 10. 2. 1 | developed world, accounting for 12% of total DALYs (Lopez,
256 III, 10. 2. 1 | health. Tobacco Control; 12:360-367~ ~Boyle P, Autier
257 III, 10. 2. 1 | once during the previous 12 months, and 65% had consumed
258 III, 10. 2. 1 | average during the previous 12 months Table 10.2.1.2.1.
259 III, 10. 2. 1 | all men (31%) than women (12%) had binged at least once
260 III, 10. 2. 1 | girls in Ireland, but only 12%-13% of boys and 5%-7% of
261 III, 10. 2. 1 | for men, accounting for 12% of all male ill-health
262 III, 10. 2. 1 | Related Clinical Problems 4: 5–12.~ ~Darke S, Kaye S (2004)
263 III, 10. 2. 1 | Schoolchildren Between the Ages of 12 and 18 Handbook for Implementing
264 III, 10. 2. 1 | delivery of methadone in 12 Member States of the European
265 III, 10. 2. 1 | with fluoride toothpaste in 12 years old children~ ~· Percentage
266 III, 10. 2. 1 | place.~ ~· Proportion of 12-year-old children according
267 III, 10. 2. 1 | tooth-brushing frequency from Finnish 12 year olds issue from the
268 III, 10. 2. 1 | 63% and 65%) of eight and 12-year-olds and about half (
269 III, 10. 2. 1 | observed among 5, 8 and 12 year olds. Among 15 year
270 III, 10. 2. 1 | of children at the age of 12 had poor oral hygiene (de
271 III, 10. 2. 1 | that almost two thirds of 12-year-olds have gingival
272 III, 10. 2. 1 | php?ID=2741] (accessed on 12 February 2008).~ ~ A (2003):
273 III, 10. 2. 1 | health status of 6- and 12-year-old schoolchildren
274 III, 10. 2. 1 | self-esteem. Sport Science Review, 12:123-155.~ ~TNS Opinion and
275 III, 10. 2. 1 | in Irish girls (27.3%, 9-12 years old) (O’Neill et al,
276 III, 10. 2. 1 | 8.6%) and Denmark (boys: 12.5%; girls: 10.3%). These
277 III, 10. 2. 1 | than 1 million deaths and 12 million life-years of ill
278 III, 10. 2. 1 | adults. Obesity Research 12:1464–1472.~ ~Boros J, Németh
279 III, 10. 2. 1 | Official Journal L 183 , 12/07/2002 P. 0051 – 0057.~[
280 III, 10. 2. 1 | Official Journal L 404 , 30/12/2006 P. 0009 – 0025 [http://
281 III, 10. 2. 1 | Official Journal L 404 , 30/12/2006 P. 0026 – 0038.~[http://
282 III, 10. 2. 1 | rep_en.pdf] (accessed on 12 May 2008).~ ~Rodler I, Bíró
283 III, 10. 2. 1 | deficiencies? Int J Nurs Pract. 12: 110-8.~ ~Chen J, Berry
284 III, 10. 2. 1 | diseases. J Neurochem. 86: 1-12.~ ~Elmadfa I, Freisling
285 III, 10. 2. 4 | Am J Public Health, 86(12): 1717-1722.~ ~Kononen J,
286 III, 10. 3. 1 | consists of a day period of 12 hours, an evening period
287 III, 10. 3. 1 | consists of a day period of 12 hours, an evening period
288 III, 10. 3. 2 | annual emissions from about 12 000 industrial facilities
289 III, 10. 3. 2 | various types of phosphorus (-12%) and the emission of dioxins/
290 III, 10. 3. 2 | round in 1987/8 included 12 European countries and indicated
291 III, 10. 3. 4 | countries26, affecting over 12 million people, with an
292 III, 10. 3. 4 | occurrence and effects of over 12.800 mass disasters in the
293 III, 10. 4. 1 | and Canada (6-city study, 12-city and 24-city study)
294 III, 10. 4. 2 | Protection Commissioner, on 12 January. 2000. The White
295 III, 10. 4. 2 | and came into force on 12 June 2004. In order to obtain
296 III, 10. 4. 2(29)| Directive 92/117/EEC(OJ L 325,12.12.2003 p. 31)~
297 III, 10. 4. 2(29)| Directive 92/117/EEC(OJ L 325,12.12.2003 p. 31)~
298 III, 10. 4. 2 | accordance with Article 12.2 of Regulation (EC) No
299 III, 10. 4. 2 | Directive 2006/122/EC of 12 December 2006) while the
300 III, 10. 4. 2(37)| vegetables (OJ L 350,14.12.1986, p 71).~
301 III, 10. 4. 2 | existing MRLs – Article 12;~· MRLs for all active substances
302 III, 10. 4. 2 | on Persistence in Soil. 12 July 2000. 9188/VI/97. Available
303 III, 10. 4. 2 | Parliament and of the Council of 12 March 2001 on the deliberate
304 III, 10. 4. 2 | European Communities No. L 12/3, 18 January 2007 Available
305 III, 10. 4. 2 | Communities No. L 183/51, 12 July 2002. Available at:~htt ~ ~
306 III, 10. 4. 2 | Official Journal L 350 , 14/12/1990. Available at:~htt ~ ~
307 III, 10. 4. 2 | Health Perspectives 112(12): 1204-1207~ ~Kallenborn,
308 III, 10. 4. 3 | outbreaks resulting in >12 000 episodes of illness
309 III, 10. 5. 1 | population across the EU is 8-12 million, mainly concentrated
310 III, 10. 5. 1 | at different tests in 10-12 y old pupils (Wargocki and
311 III, 10. 5. 1 | Environmental Health 15(1-2): 1-12.~Loftness V, Hakkinen B,
312 III, 10. 5. 2 | rural settings.~ ~Figure 10.5.2.12. Infection prevalence in
313 III, 10. 5. 2 | Services Research 2004, 4:12.~[http://www.biomedcentral.
314 III, 10. 5. 2 | biomedcentral.com/1472-6963/4/12] (accessed on 19 September
315 III, 10. 5. 2 | different.html] (accessed on 12 April 2007)~ ~Netherlands
316 III, 10. 5. 2 | ruralhealth.pdf] (accessed on 12 November 2007)~ ~
317 III, 10. 5. 3 | absence during the previous 12 months. Furthermore, perceived
318 III, 10. 5. 3 | individuals during the past 12 month which irrespective
319 III, 10. 5. 3 | problems at least once in 12 months (Table 10.5.3.1).
320 III, 10. 5. 3 | Absence from work in last 12 month due to health problems~ ~
321 III, 10. 5. 3 | million Euro for Austria and 12.6 for Belgium. In many countries,
322 III, 10. 5. 3 | agriculture (table 10.5.3.12). A lack of job control
323 III, 10. 5. 3 | communication.~ ~Table 10.5.3.12. Work organisational risks
324 III, 10. 5. 3 | from 17% in Finland and 12% in the Netherlands to 3%
325 III, 10. 5. 3 | absenteeism in the range of 12% to 36% with a return-on-investment
326 III, 10. 5. 3 | European Journal of Neurology 12 (Supplement 1):1-27.~Ashton
327 III, 10. 5. 3 | Directive 89/391/EEC of 12 June 1989 on the introduction
328 III, 10. 6. 1 | network members over the last 12 months. Another dimension
329 III, 10. 6. 1 | social support and scores 12-14 strong social support.~ ~
330 IV, 11. 1. 5 | have hospitals stays 8 to 12 days longer than they should (
331 IV, 11. 1. 6 | including 8 (1%), 214 (12%), and 18 hospitals respectively).
332 IV, 11. 5. 3 | transplantation (figure 11.12) organ exchange and organ
333 IV, 11. 5. 3 | European countries~Figure 11.12. Organ transplantation in
334 IV, 11. 5. 3 | events, whereas in other 12 the system is driven by
335 IV, 11. 5. 4 | In spite of this, only 12% of Europeans currently
336 IV, 11. 6. 2 | Latvia). As shown in Table 11.12, the countries with predominantly
337 IV, 11. 6. 2 | insurance funds.~ ~Table 11.12. Financing mix separated
338 IV, 11. 6. 5 | Netherlands." Euro Health 12(2): 7-9.~ ~Belli P (2003):
339 IV, 11. 6. 5 | Journal of Medicine 335(12): 891-894.~ ~Boyle S (2007): "
340 IV, 11. 6. 5 | for Quality in Health Care 12(4): 281-295.~ ~Bunker J,
341 IV, 11. 6. 5 | for Quality in Health Care 12(2): 133-42.~ ~Cheah TS (
342 IV, 11. 6. 5 | Journal of Health Economics 12: 431-57.~ ~Cutler DM (2002): "
343 IV, 12 | 12. INSTITUTIONAL AND POLICY
344 IV, 12. 1 | 12.1. Introduction~ ~A number
345 IV, 12. 1 | initiatives in the field (Table 12.1). Even today, public health
346 IV, 12. 1 | State competence.~ ~Table 12.1. Health – related precursor
347 IV, 12. 1 | Article 152(1)) (Table 12.2). Whilst the Amsterdam
348 IV, 12. 1 | is not surprising (Table 12.2).~ ~Table 12.2. EU Treaty
349 IV, 12. 1 | surprising (Table 12.2).~ ~Table 12.2. EU Treaty Articles concerning
350 IV, 12. 1 | billion citizens (Table 12.3). Prevention has the potential
351 IV, 12. 1 | public expectations.~ ~Table 12.3. Some examples highlighting
352 IV, 12. 1 | of the Treaty (see Table 12.3), related to the movement
353 IV, 12. 2 | 12.2. The European strategy
354 IV, 12. 2 | principle (see Section 12.7.), and is likely to make
355 IV, 12. 2 | some examples, see Tables 12.4 and 12.5.~ ~Table 12.4.
356 IV, 12. 2 | examples, see Tables 12.4 and 12.5.~ ~Table 12.4. Policies
357 IV, 12. 2 | Tables 12.4 and 12.5.~ ~Table 12.4. Policies and control
358 IV, 12. 2 | been officially launched on 12 June 2007 at the European
359 IV, 12. 2 | seriously.~ ~In 2005, only 12 of the 25 (IDF Europe/FEND
360 IV, 12. 2 | starting in 2007. ~ ~ ~ ~Table 12.5. Policies and control
361 IV, 12. 3 | 12.3. The reviewed European
362 IV, 12. 4 | 12.4. Co-ordination mechanisms
363 IV, 12. 4 | other than D.G. SANCO (Table 12.6).~ ~Table 12.6. Health
364 IV, 12. 4 | SANCO (Table 12.6).~ ~Table 12.6. Health across the European
365 IV, 12. 4 | health policy makers (Table 12.7). Working as technical
366 IV, 12. 4 | established in 2006.~Table 12.7. Community agencies directly
367 IV, 12. 4 | health is provided in Table 12.8.~ ~ ~Table 12.8. Financial
368 IV, 12. 4 | in Table 12.8.~ ~ ~Table 12.8. Financial community instruments
369 IV, 12. 5 | 12.5. The European Public Health
370 IV, 12. 5 | on multiple lines (Table 12.9).~ ~Table 12.9. Actions
371 IV, 12. 5 | lines (Table 12.9).~ ~Table 12.9. Actions referred to in
372 IV, 12. 5 | collection and use (see Annex 12.1).~ ~ ~Annex 12.1. System
373 IV, 12. 5 | see Annex 12.1).~ ~ ~Annex 12.1. System of European Community
374 IV, 12. 5 | Jagger, in press).~ ~Figure 12.A1.1a Trend in the proportion
375 IV, 12. 5 | Member States - men.~ ~Figure 12.A1.1b Trend in the proportion
376 IV, 12. 6 | 12.6. The Public Health Forum~ ~
377 IV, 12. 7 | 12.7. Health in all policies~ ~
378 IV, 12. 7 | declaring success.~ ~Annex 12.2. Declaration on Health
379 IV, 12. 8 | 12.8. International initiatives~ ~
380 IV, 12. 8 | 27 member States (Table 12.10) started in the health
381 IV, 12. 8 | December 2005.~ ~ ~Table 12.10. The 27 European Union
382 IV, 12. 9 | 12.9. The cooperation with
383 IV, 12. 10 | 12.10. Policy developments
384 IV, 12. 10 | European level (see Annex 12.3). Through their priorities
385 IV, 12. 10 | Community level (see Annex 12.3).~ ~Annex 12.3 Priorities
386 IV, 12. 10 | see Annex 12.3).~ ~Annex 12.3 Priorities and initiatives
387 IV, 12. 10 | States is given in Annex 12.4.~ ~Annex 12.4. Initiatives
388 IV, 12. 10 | given in Annex 12.4.~ ~Annex 12.4. Initiatives adopted at
389 IV, 12. 10 | 1973, young people aged 12 to 25 years) and Promoting
390 IV, 12. 10 | youth (adolescents aged 12 to 19), both conducted/coordinated
391 IV, 12. 10 | 1973, young people aged 12 to 25 years) conducted/coordinated
392 IV, 12. 10 | health for children until 12 years is given, includes
393 IV, 12. 10 | 76017 (1-8-2002) and 82942 (12-9-2003) smoking is forbidden
394 IV, 12. 10 | Duration: 01/07/2006-31/12/2007) ~The SAFE project,
395 IV, 12. 10 | health~ high~Decision 1877/12/2005 National plan of action
396 IV, 13. 2. 2 | than 1 million deaths and 12 million life-years of ill
397 IV, 13. 2. 2 | EU accounting for about 12% of disability adjusted
398 IV, 13. 9 | in Europe. Eur J Neurol 12 Suppl 1:1-27.~EPC (Economic
|
|
| |
